Close Menu

NEW YORK, July 31 – Exelixis of South San Francisco, Calif., has appointed Jeffrey Latts chief medical officer and senior vice president for clinical development.

The appointment comes as part of Exelixis plans to step up its drug discovery efforts and advances a newly acquired drug through clinical trials.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.